Related Experiment Videos
Management of dyslipidemia in patients with HIV disease
1Department of Clinical and Experimental Medicine, Division of Infectious Diseases, University of Bologna, S. Orsola Hospital, Bologna, Italy.
Insights
Serum lipid abnormalities in HIV disease are not well understood, especially with antiretroviral therapy. Careful monitoring and tailored interventions are crucial for managing HIV-related dyslipidemia and preventing complications.
Area of Science:
- Infectious Diseases
- Cardiovascular Medicine
- Pharmacology
Background:
- Serum lipid abnormalities in HIV disease are poorly understood, particularly concerning antiretroviral therapy.
- Limited data exist on managing HIV-related dyslipidemia and the efficacy of interventions like diet, exercise, and hypolipidemic agents.
Purpose of the Study:
- To review the current understanding of lipid abnormalities in HIV disease.
- To discuss the management strategies for HIV-associated dyslipidemia, including dietary, exercise, and pharmacological approaches.
- To highlight the challenges in selecting appropriate hypolipidemic agents due to lack of controlled studies and potential drug interactions.
Main Methods:
- Literature review of epidemiological, etiopathogenetic, laboratory, and clinical features of dyslipidemia in HIV.
- Discussion of management options based on available literature and clinical experience.
- Analysis of challenges in hypolipidemic agent selection for HIV patients.
Main Results:
- Antiretroviral therapy, especially protease inhibitors, can significantly impact serum lipid profiles.
- Effective management requires careful monitoring of lipid profiles during combination antiretroviral therapy.
- There is a lack of controlled studies on hypolipidemic treatments in HIV-associated dyslipidemia.
Conclusions:
- Close monitoring of serum lipids is essential during combination antiretroviral therapy for HIV patients.
- Dietary and exercise interventions, alongside judicious use of hypolipidemic agents, are necessary to prevent long-term dyslipidemia complications.
- Specific guidelines for treating hypertriglyceridemia and hypercholesterolemia in HIV infection are needed.
Abstract:
The epidemiological, etiopathogenetic, laboratory and clinical features of serum lipid abnormalities occurring in the course of HIV disease are still poorly understood (especially when the supporting role of single antiretroviral compounds is considered), while limited literature data are to date available regarding the management of HIV-related dyslipidemia, as well as the efficacy and safety of dietary-exercise programs, and that of selected hypolipidemic agents. At this time, a careful monitoring of serum lipid profile is needed during combination antiretroviral therapy including protease inhibitors, in order to suggest a diet and hypolipidemic treatment when applicable, and to prevent clinical sequelae related to long-term dyslipidemia. The selection of an appropriate hypolipidemic agent is difficult, since no controlled studies are available in this field, and possibly increased risks of pharmacologic interactions, toxicity and impaired patient's adherence should be taken into consideration. Waiting for specific guidelines for the treatment of hypertriglyceridemia and hypercholesterolemia in the setting of HIV infection, all available literature reports dealing with the management of HIV-associated hyperlipidemia are briefly discussed, on the basis of personal clinical experience.